177 related articles for article (PubMed ID: 30232722)
1. Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis.
He Q; Liao BH; Xiao KW; Zhou L; Feng SJ; Li H; Wang KJ
Int Urol Nephrol; 2018 Dec; 50(12):2113-2121. PubMed ID: 30232722
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence.
Jo JK; Kim K; Lee SE; Lee JK; Byun SS; Hong SK
Ann Surg Oncol; 2016 May; 23(5):1760-7. PubMed ID: 26717939
[TBL] [Abstract][Full Text] [Related]
4. Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
Flores JM; Vertosick E; Jenkins LC; Cooper J; Benfante N; Sjoberg D; Vickers AJ; Eastham JA; Laudone VP; Scardino PT; Nelson CJ; Mulhall JP
J Urol; 2024 Mar; 211(3):400-406. PubMed ID: 38194487
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Phosphodiesterase 5 Inhibitor on Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer.
Chung JW; Kim JW; Ha YS; Choi SH; Lee JN; Kim BS; Kim HT; Yoo ES; Kwon TG; Kim TH
Urol J; 2019 Jun; 16(3):255-259. PubMed ID: 31204438
[TBL] [Abstract][Full Text] [Related]
6. Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
Aoun F; Slaoui A; Walid AHO; Albisinni S; Assenmacher G; de Plaen E; Azzo JM; Peltier A; Roumeguère T
Prog Urol; 2018 Oct; 28(12):560-566. PubMed ID: 30201551
[TBL] [Abstract][Full Text] [Related]
7. Effect of phosphodiesterase type 5 inhibitors on prostate cancer risk and biochemical recurrence after prostate cancer treatment: A systematic review and meta-analysis.
Wu Y; Qu X; Wang Y; Xia J; Gu Y; Qian Q; Hong Y
Andrologia; 2019 Mar; 51(2):e13198. PubMed ID: 30443968
[TBL] [Abstract][Full Text] [Related]
8. A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.
Gallina A; Bianchi M; Gandaglia G; Cucchiara V; Suardi N; Montorsi F; Briganti A
Eur Urol; 2015 Nov; 68(5):750-3. PubMed ID: 25700565
[TBL] [Abstract][Full Text] [Related]
9. Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies.
Zhang L; Wu B; Zha Z; Zhao H; Jiang Y; Yuan J
World J Surg Oncol; 2018 Jul; 16(1):124. PubMed ID: 29970100
[TBL] [Abstract][Full Text] [Related]
10. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.
Limoncin E; Gravina GL; Corona G; Maggi M; Ciocca G; Lenzi A; Jannini EA
Andrology; 2017 Sep; 5(5):863-872. PubMed ID: 28787547
[TBL] [Abstract][Full Text] [Related]
11. Back to baseline: erectile function recovery after radical prostatectomy from the patients' perspective.
Nelson CJ; Scardino PT; Eastham JA; Mulhall JP
J Sex Med; 2013 Jun; 10(6):1636-43. PubMed ID: 23551767
[TBL] [Abstract][Full Text] [Related]
12. Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.
Kimura M; Caso JR; Bañez LL; Koontz BF; Gerber L; Senocak C; Donatucci CF; Vujaskovic Z; Moul JW; Polascik TJ
BJU Int; 2012 Dec; 110(11 Pt C):E931-8. PubMed ID: 22520165
[TBL] [Abstract][Full Text] [Related]
13. Utilization of pharmacotherapy for erectile dysfunction following treatment for prostate cancer.
Prasad MM; Prasad SM; Hevelone ND; Gu X; Weinberg AC; Lipsitz SR; Palapattu GS; Hu JC
J Sex Med; 2010 Mar; 7(3):1062-73. PubMed ID: 20059662
[TBL] [Abstract][Full Text] [Related]
14. Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy.
Kim SJ; Kim JH; Chang HK; Kim KH
J Exerc Rehabil; 2016 Jun; 12(3):143-7. PubMed ID: 27419107
[TBL] [Abstract][Full Text] [Related]
15. Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series.
Hubanks JM; Umbreit EC; Karnes RJ; Myers RP
Eur Urol; 2012 May; 61(5):878-84. PubMed ID: 22154730
[TBL] [Abstract][Full Text] [Related]
16. Chronology of erectile function in patients with early functional erections following radical prostatectomy.
Katz D; Bennett NE; Stasi J; Eastham JA; Guillonneau BD; Scardino PT; Mulhall JP
J Sex Med; 2010 Feb; 7(2 Pt 1):803-9. PubMed ID: 19796019
[TBL] [Abstract][Full Text] [Related]
17. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function.
Basal S; Wambi C; Acikel C; Gupta M; Badani K
BJU Int; 2013 Apr; 111(4):658-65. PubMed ID: 23186312
[TBL] [Abstract][Full Text] [Related]
18. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
Boorjian SA; Bianco FJ; Scardino PT; Eastham JA
BJU Int; 2005 Oct; 96(6):773-6. PubMed ID: 16153197
[TBL] [Abstract][Full Text] [Related]
19. The "Kiel Concept" of Long-Term Administration of Daily Low-Dose Sildenafil Initiated in the Immediate Post-Prostatectomy Period: Evaluation and Comparison With the International Literature on Penile Rehabilitation.
Osmonov DK; Jünemann KP; Bannowsky A
Sex Med Rev; 2017 Jul; 5(3):387-392. PubMed ID: 28372960
[TBL] [Abstract][Full Text] [Related]
20. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]